Abstract:Background: Lophine is one of the new core moiety with the substitution of three phenyl rings at the 2nd, 4th, and 5th position of the imidazole. Lophine is not explored in the development of drug molecules. In this research, we have designed 30 lophine derivatives with different substituted functional groups. The designed compounds were evaluated through different in-silico tools and software to check their properties for different biological receptors. Methods: A molecular docking study was carried out on different receptors i.e. EGFR for anti-cancer, COX-1, and COX-2 for anti-inflammatory, fungal oxidoreductase for anti-fungal, bacterial DNA gyrase for anti-bacterial and TNF-α, which co-relates different type of inflammatory diseases. Further, ADMET of the top docked compounds were carried out in SwissADME and ProTox-II webserver. The MD simulation was carried out to check the stability of the compounds inside the binding pocket of the different proteins. Finally, the common pharmacophore was generated by the PharmaGist web server. Results: The molecular docking results revealed that the SAP-28 has significant binding energies -9.8, -9.6, and -10.0 kcal/mol against EGFR, fungal oxidoreductase, and TNF-α receptors respectively. SAP-26 has potent interaction -9.8 and -11.0 kcal/mol against EGFR and COX-2 receptors respectively. Whereas, SAP-25 and SAP-19 showed the best interaction for bacterial DNA gyrase (-8.9 kcal/mol) and COX-1 receptor (-9.7 kcal/mol) respectively. To enhance the acceptability top docked compounds, the ADME parameters along with toxicity analysis were carried out where all the compounds showed acceptable results. Furthermore, the stability of the protein-ligand complexes was determined by a 100 ns MD simulation analysis, and compounds were found stable. The common pharmacophore was generated with the help of the top compounds in the PharmaGist web server. Conclusion: This in-silico study established that, various substitutions on the phenyl ring present in the 2nd position of the imidazole such as 2-hydroxy, 2-methyl, 3-methyl, 4-pyridinyl, etc. governing their ability to interact with diverse targets. The compound can contribute a major role in the development of different leads in the future. result: The molecular docking results revealed that the SAP-28 has significant binding energies -9.8, -9.6 and -10.0 kcal/mol against EGFR, fungal oxidoreductase, and TNF-α receptors respectively. SAP-26 has potent interaction -9.8 and -11.0 kcal/mol against EGFR and COX-2 receptors respectively. Whereas, SAP-25 and SAP-19 showed the best interaction for bacterial DNA gyrase (-8.9 kcal/mol) and COX-1 receptor (-9.7 kcal/mol) respectively. To enhance the acceptability top docked compounds, the ADME parameters along with toxicity analysis were carried out where all the compounds showed acceptable results. Furthermore, the stability of the protein-ligand complexes were determined by a 100 ns MD simulation analysis. The common pharmacophore was generated with the help of the top compounds in the PharmaGist web server.

Designing of Sulfanilamide/Sulfacetamide Derivatives as Human Topoisomerase II Inhibitor: A Docking Approach

A Rational Approach to Anticancer Drug Design: 2D and 3D- QSAR, Molecular Docking and Prediction of ADME Properties Using Silico Studies of Thymidine Phosphorylase Inhibitors

Synthesis, Molecular Docking and Antitumor Activity of New Dithiazoles

Design, Synthesis, Computational Docking and Biological Evaluation of Novel 4-Chloro-1,3-Benzoxazole Derivatives as Anticancer Agents

Molecular docking, synthesis and biological significance of pyrimidine analogues as prospective antimicrobial and antiproliferative agents

In Silico and In Vitro Investigation of Cytotoxicity and Apoptosis of Acridine/Sulfonamide Hybrids Targeting Topoisomerases I and II

Crystal Structures, Molecular Docking and In Vitro Investigations of Two 4-Substituted 2-(5,5-dimethyl-3-styrylcyclohex-2-enylidene)malononitrile Derivatives as Potential Topoisomerase II Inhibitors

In-silico studies of 2-aminothiazole derivatives as anticancer agents by QSAR, molecular docking, MD simulation and MM-GBSA approaches

In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies

A MOLECULAR MODELLING APPROACH FOR STRUCTURE-BASED VIRTUAL SCREENING AND IDENTIFICATION OF NOVEL ISOXAZOLES AS POTENTIAL ANTIMICROBIAL AGENTS AGAINST S. AUREUS

Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,4-oxadiazole incorporated indazole-isoxazole derivatives

Design and Discovery of Lophine Derivatives as Multi-targeting Agents by Molecular Docking, ADMET, MD Simulation and Pharmacophore Analysis: A Computational Approach

Design and synthesis of a potential candidate molecule designated as Diosgenin-Aceclofenac ester as an anticancer agent on SiHa cell line, it's spectroscopic, DFT and molecular docking studies

A computer-aided drug design approach to explore novel type II inhibitors of c-Met receptor tyrosine kinase for cancer therapy: QSAR, molecular docking, ADMET and molecular dynamics simulations

In-silico Designing, ADMET Analysis, Synthesis and Biological Evaluation of Novel Derivatives of Diosmin Against Urease Protein and Helicobacter pylori Bacterium

Effects of yeast culture addition (Saccharomyces cerevisiae) to Anatolian water buffalo diets on milk composition and somatic cell count.

Investigation on synthesized sulfonamide Schiff base with DFT approaches and in silico pharmacokinetic studies: Topological, NBO, and NLO analyses

Computer Assisted Drug Design of Tinosporide for treatment of Cancer: a Combined Density Functional and Molecular Docking Study

In-silico design novel phenylsulfonyl furoxan and phenstatin derivatives as multi-target anti-cancer inhibitors based on 2D-QSAR, molecular docking, dynamics and ADMET approaches

Design, Synthesis, Anticancer Evaluation and Molecular Docking Studies of Amide Derivatives of Thienopyrimidine Isoxazoles

MOLECULAR DOCKING, BINDING ENERGY AND MOLECULAR DYNAMICS SIMULATION STUDIES OF PIPERAZIN-1-YLPYRIDAZINE DERIVATIVES AS DCTPASE INHIBITORS